NEW YORK – Adaptive Biotechnologies said Monday that its strategic collaboration and license agreement with Genentech for cancer cell therapy development has been terminated effective Feb. 9, 2026.

纽约——Adaptive Biotechnologies周一表示，其与Genentech就癌症细胞疗法开发达成的战略合作和许可协议将于2026年2月9日终止。

In a regulatory filing with the US Securities and Exchange Commission, Adaptive said the companies will 'wind down activities' under the agreement, which was initiated in December 2018. Upon termination, Adaptive will be released from exclusivity obligations with respect to cell therapies in oncology, the company said..

在向美国证券交易委员会提交的监管文件中，Adaptive 表示，根据 2018 年 12 月签署的协议，两家公司将“逐步停止活动”。该公司表示，协议终止后，Adaptive 将不再承担与肿瘤学细胞疗法相关的排他性义务。

As a result of the termination, Adaptive said it expects to recognize $33.7 million during the second half of 2025 in noncash revenues from the remaining amortization of the cash consideration received under the agreement.

由于协议终止，Adaptive公司表示，预计在2025年下半年将从协议中收到的现金对价的剩余摊销中确认3370万美元的非现金收入。

In an email, a spokesperson from Adaptive said Genentech made the decision to terminate the agreement 'following thoughtful consideration, which was not based on any emerging safety concerns.'

在一封电子邮件中，Adaptive公司的发言人表示，Genentech经过深思熟虑后作出了终止协议的决定，“这个决定并非基于任何新出现的安全问题。”

'Genentech let us know that it highly values us as an innovative company and partner and recognizes the efforts that both companies have contributed to this collaboration over the last six and half years,' the spokesperson noted.

“基因泰克让我们知道，它高度认可我们作为一家创新公司和合作伙伴的价值，并认可两家公司过去六年半中为这一合作所作出的努力，”发言人指出。

Adaptive and Genentech

自适应和基因泰克

signed the agreement

签署了协议

to leverage the former's T-cell receptor (TCR) screening platform to help the drug company develop personalized cancer therapies.

利用前者的T细胞受体（TCR）筛选平台，帮助制药公司开发个性化癌症疗法。

Under the terms of the deal, Adaptive said it would use the platform to identify TCRs that could be used to target individual cancer patients' neoantigens. It would also handle patient-specific screening worldwide. Meanwhile, San Francisco-based Genentech said it would engineer and manufacture personalized therapies based on these TCRs and be responsible for clinical, regulatory, and commercialization activities..

根据协议条款，Adaptive 表示将使用该平台来识别可用于靶向个体癌症患者新抗原的 TCR。它还将负责全球范围内的患者特异性筛查。同时，总部位于旧金山的 Genentech 表示，将基于这些 TCR 开发和制造个性化疗法，并负责临床、监管和商业化活动。

Adaptive on Monday reiterated its business goals for its immune medicine business arm, including developing and deploying digital TCR-antigen prediction models that enable novel immunology applications and partnering opportunities as well as developing a preclinical data package for the lead T-cell depletion program in autoimmunity.

周一，Adaptive公司重申了其免疫医学业务部门的商业目标，包括开发和部署数字TCR-抗原预测模型，以实现新颖的免疫学应用和合作机会，以及为自身免疫领域领先的T细胞耗竭项目开发临床前数据包。

.

。

In morning trading on the Nasdaq, shares of Adaptive were down 6 percent at $12.27.

在纳斯达克早盘交易中，Adaptive的股价下跌6％，至12.27美元。